Research Article
Constructing a Novel Prognostic Signature Based on TGF-β Signaling for Personalized Treatment in Pancreatic Adenocarcinoma
Figure 8
Sensitivity analysis to immunotherapy and chemotherapy in TCGA-PAAD dataset. (a) SubMap analysis between TCGA-PAAD and IMvigor210 datasets. SD/PD indicates the group of stable disease (SD) and progressive disease (PD). CR/PR indicates the group of complete response (CR) and partial response (PR). Chi-square test was performed. (b–f) Comparision of estimated IC50 of cisplatin (b) erlotinib (c), sorafenib (d) paclitaxel (e) and crizotinib (f) between high-risk and low-risk groups. Student t test was performed. , .
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |